United Bank Acquires 4,332 Shares of Bristol-Myers Squibb Co (BMY)

United Bank lifted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 20.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 25,293 shares of the biopharmaceutical company’s stock after buying an additional 4,332 shares during the quarter. United Bank’s holdings in Bristol-Myers Squibb were worth $1,570,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Wealth Architects LLC increased its stake in Bristol-Myers Squibb by 14.0% during the 3rd quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 848 shares during the period. Beech Hill Advisors Inc. increased its stake in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock valued at $6,549,000 after buying an additional 850 shares during the period. Signature Financial Management Inc. increased its stake in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock valued at $2,546,000 after buying an additional 870 shares during the period. Mcmillion Capital Management Inc. increased its stake in Bristol-Myers Squibb by 1.4% during the 2nd quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after buying an additional 903 shares during the period. Finally, Securian Asset Management Inc increased its stake in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after buying an additional 912 shares during the period. Institutional investors own 72.54% of the company’s stock.

BMY has been the topic of several research analyst reports. Barclays raised their target price on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Friday, October 12th. Morgan Stanley lowered their target price on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday. Credit Suisse Group set a $61.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, October 14th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research note on Friday, October 5th. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, October 19th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $62.48.

Shares of BMY opened at $52.81 on Friday. The company has a market capitalization of $83.81 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 1.43 and a beta of 1.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb Co has a 12-month low of $46.94 and a 12-month high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. As a group, research analysts forecast that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were paid a $0.40 dividend. The ex-dividend date was Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 3.03%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

ILLEGAL ACTIVITY WARNING: “United Bank Acquires 4,332 Shares of Bristol-Myers Squibb Co (BMY)” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.wkrb13.com/2018/11/10/united-bank-acquires-4332-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Book Value Per Share – BVPS

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply